Analysts at Leerink Partnrs raised their FY2026 EPS estimates for shares of Travere Therapeutics in a research note issued to investors on Tuesday, February 11th. Leerink Partnrs analyst J. Schwartz ...

Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Gilead Sciences in a report ...

Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market ...

Leerink analyst Michael Cherny upgraded CVS Health (CVS) to Outperform from Market Perform with a price target of $75, up from $55. The firm ...

Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for CVS Health (NYSE:CVS) from Market ...

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Nkarta (NKTX – Research Report) yesterday and set a price target of $7.00.

U.S. District Judge Angel Kelley for the District of Massachusetts allowed state law claims to move forward in a suit brought by an investment banker who claims Leerink Partners failed to pay minimum ...

An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied ...

Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is ...

Upstart investment bank SVB Leerink is no longer keeping mum on its ambitions to push into the red hot technology, media, and telecommunications market. The dealmaking unit of SVB Financial Group ...

Fintel reports that on February 7, 2025, Leerink Partners upgraded their outlook for Doximity (NYSE:DOCS) from Market Perform to Outperform. As of January 29, 2025, the average one-year price ...